Study on the hydrolysis mechanism of phosphodiesterase 4 using molecular dynamics simulations

Molecular Simulation

Volumn 32, Issue 5, 2006, Pages 369-374

  Kang, N S ^a   Chae, C H ^a   Yoo, S E ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

cAMP; Hydration pattern; Hydrolysis mechanism; Molecular dynamics simulation; PDE4

Indexed keywords

COMPUTER SIMULATION; DRUG PRODUCTS; HYDRATION; HYDROGEN BONDS; HYDROLYSIS; MOLECULAR DYNAMICS;

CAMP; HYDRATION PATTERN; HYDROLYSIS MECHANISM; MOLECULAR DYNAMICS SIMULATION;

ENZYMES;

EID: 33748534489     PISSN: 08927022     EISSN: 10290435     Source Type: Journal    
DOI: 10.1080/08927020600717111     Document Type: Article

References (27)

1. J.A. Beavo. Cyclic nucleotide. phosphodiesterases; functional implications of multiple isoforms. Physiol, Rev., 75, 725 (1995).
2. M. Conti. Phosphodiesterases and cyclic nucleotide. signaling in endocrine cells. Mol. Endocrinol., 14, 1317 (2002).
3. M. Conti, S.L. Jon. The molecular biology of cyclic nucleotide. phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol., 63, 1 (1999).
4. S.H. Soderling, J.A. Beavo. Regulation of cAMP and cGMP signaling; new phosphodiesterases and new functions. Curr. Opin. Cell. Biol., 12, 174 (2000).
5. S.H. Francis, I.V. Turko, J.D. Corbin. Cyclic nucleotide. phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol., 65, 1 (2001).
6. L.C. Graeme, P.E. Bruce, Y. Suzuki, D. Fong, B. Powell, B.H. Lee, C. Luu, M. Tabrizizad, S. Gillette, P.N. Ibrahim, D.R. Artis, O. Bollag, M.V. Milburn, S.H. Kim, J. Schiessinger, K.Y.J. Zhang. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure, 12, 2233 (2004).
7. K.Y.J. Zhang, G.L. Card, Y. Suzuki, D.R. Artis, D. Fong, S. Gillette, D. Hsieh, J. Neiman, B.L. West, C. Zhang, M.V. Milburn, S.H. Kim, J. Schiessinger, G. Bollag. A glutamine switch mechanism: short article for nucleotide. selectivity by phosphodiesterases. Mol. Cells, 15, 279 (2004).
8. J.A. Beavo, L.L. Brunton. Cyclic nucleotide. research still expanding after half a century. Nat. Rev. Mol. Cell Biol., 3, 710 (2002).
9. C. Mehats, C.B. Anderson, M. Filopani, S.L. Jin, M. Conti. Cyclic nucleotide. phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol. Metab., 13, 29 (2002).
10. T.J. Torphy, G.P. Livi, S.B. Christensen. Novel phosphodiesterase inhibitors for the therapy of asthma. Drug News Perspect., 6, 537 (1993).
11. M.N. Palfreyman. Phosphodiesterase inhibitors as antiasthmatic agents. In Annual Reports in Medicinal Chemistry, Vol.29, p. 185, Academic Press, New York (1994).
12. P. Norman. PDE4 inhibitors 1998. Expert Opin. Ther. Pat., 8, 771 (1998).
13. M.M. Teixeira, R.W. Gristwood, N. Cooper, P.O. Hallewell. Phosphodiesterase (PDE) 4 inhibitors; anti-inflammatory drugs of the future? TIPS, 18, 164 (1997).
14. Q. Huai, J. Colicelli, H. Ke. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterases catalysts. Biochemistry, 42, 13220 (2003).
15. Q. Huai, Y. Liu, S.H. Francis, J.D. Corbin, H. Ke. Crystal structure of phosphodiesterases 4 and 5 in complex with inhibitor IBMX suggest a conformation determinant of inhibitor selectivity. J. Biol. Chem., 279, 13095 (2003).
16. Q. Huai. H. Wang, Y. Sun, H.Y. Kim, Y. Liu, H. Ke. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure (Camb), 11, 865 (2003).
17. Q. Huai, H. Wang, W. Zhang, R.W. Colman, H. Robinson, H. Ke. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc. Natl. Acad. Sci. USA, 101, 9624 (2004).
18. M.E. Lee, J. Markowitz, J.O. Lee, H. Lee. Crystal structure of phosphodiesterase 4D and inhibitor complex. FEBS Lett., 530, 53 (2002).
19. G. Scapin, S.B. Patel, C. Chung, J.P. Varnerin, S.D. Edmondson, A. Mastracchio, E.R. Parmee, S.B. Singh, J.W. Becker, L.H. Van Der Ploeg. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry, 43, 6091 (2004).
20. B.J. Sung, K. Yeon Hwang, Y. Ho Jeon, J.I. Lee, Y.S. Heo, J. Hwan Kim, J. Moon, J. Min Yoon, Y.L. Hyun, E. Kim, J.E. Sung, S.Y. Park, J.O. Lee, T.G. Lee, S.G. Ro, J.M. Choe. Structure of the catalytic domain of human phosphodiesterases 5 with bound drug molecules. Nature, 425, 98 (2003).
21. R.X. Xu, W.J. Rocque, M.H. Lambert, D.E. Vanderwall, M.A. Luther, R.T. Nolte. Crystal structure of the catalytic domain of phosphodiesterase 4B complexed with amp 8-br-AMP, and rolipram. J. Mol. Biol., 337, 355 (2004).
22. B.R. Brooks, R.E. Bruccoleri, B.D. Olafson, D.J. States, S. Swaminathan, M. Karplus. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comp. Chem., 4, 187 (1983).
23. W. Jorgensen, J. Chandrasekhar, J. Madura, R. Imprey, M. Klein. Comparison of simple potential functions for simulating liquid waters. J. Chem. Phys., 79, 926 (1983).
24. S.E. Feller, Y. Zhang, R.W. Pastor. Constant pressure molecular dynamics simulation: the Langevin piston method. J. Chem. Phys., 103, 4613 (1995).
25. 2- ion pair in aqueous solution. Chem. Phys. Lett., 364, 580 (2002).
26. D.H. Jung, N.S. Kang, M.S. Jhon. Site-directed mutation study on hyper thermostability of rubredoxin from pyrococcus furiosus using molecular dynamics simulations in solution. J. Phys. Chem., 101, 466 (1997).
27. S. Jacobitz, M.D. Ryan, M.M. McLaughlin, G.P. Livi, W.E. Dewolf, T.J. Torphy. Role of conserved histidines in catalytic activity and inhibitor binding of human recombinant phosphodiesterase 4A. Mol. Pharmacol., 51, 999 (1997).